Yes. Two companies have been listed and two have been sold:
LIDDS AB was listed on the Nasdaq First North (Stockholm, Sweden) in 2014.
AcuCort AB was listed on Spotlight Stock Market in Stockholm, Sweden in 2017. Aqilion has remained the main shareholder with approximately 26% of shares (Oct 2019).
Ambria Dermatology AB was sold after Aqilion (legacy PULS) had run the project for five years in 2009. Ambria Dermatology developed a technological platform to prolong the lifecycle of dermatological and hygiene products. The profits were three times the invested capital.
DuoCort Pharma AB developed Plenadren® (a medication for treating adrenal insufficiency) and was sold in 2011 to an American pharmaceutical company (ViroPharma, now known as Shire). DuoCort Pharma (subsidiary of Pulsetten AB) was started and run by Aqilion (legacy PULS) for seven years and the final value of the sale was more than SEK 1 billion, or 12 times the invested capital.
In order for Aqilion to be a sustainable company, it is essential that the company continues to be extremely careful about exiting the projects that do not meet the goals that have been set, and to do so in time. Therefore, Aqilion has decided to discontinue to invest in five projects:
Pharmapnea AB was discontinued in 2014. Adenovir Pharma AB and Trophea begun the liquidation processes during the fourth quarter of 2019.
During 2019, Aqilion has also sold its holdings in the project company Belina AB to its founder and the entire stake in the portfolio company Glactone Pharma AB to Daniel Lifveredson Invest AB.